Vivo Bio Tech Limited

Equities

VIVOBIOT6

INE380K01017

Biotechnology & Medical Research

Market Closed - Bombay S.E. Other stock markets 06:00:59 2024-07-10 am EDT			5-day change	1st Jan Change
37.63 ^INR	-2.23%		-7.36%	+13.69%

May. 20	Vivo Bio Tech Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
May. 20	Vivo Bio Tech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Vivo Bio Tech Limited Appoints Karthik Allenkala as Whole Time Company Secretary, Compliance Officer and Key Managerial Personnel of the Company

August 28, 2019 at 09:41 am EDT

Vivo Bio Tech Limited at its board meeting held on August 28, 2019 appointed Mr. Karthik Allenkala, as Whole Time Company Secretary and designated as compliance Officer and Key Managerial personnel of the company.

Latest news about Vivo Bio Tech Limited

Vivo Bio Tech Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 20	CI
Vivo Bio Tech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 20	CI
Vivo Bio Tech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Vivo Bio Tech Limited Appoints Vaishnavi Kiran Ayinampudi as Company Secretary & Compliance Officer	Jan. 23	CI
Vivo Bio Tech Limited Announces the Resignation of Ms. Jyotika Aasat as Company Secretary & Compliance Officer of the Company with Effect from January 02, 2024	Dec. 23	CI
Vivo Bio Tech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 14	CI
Vivo Bio Tech Limited Announces the Resignation of Hariharan Ravindran as Independent Director	23-08-31	CI
Vivo Bio Tech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-07	CI
Vivo Bio Tech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-30	CI
Vivo Bio Tech Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-30	CI
Vivo Bio Tech Limited Announces Resignation of Sunder Kanaparthy as Independent Director, Effective from April 1, 2023	23-03-31	CI
Vivo Bio Tech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Vivo Bio Tech Limited announced a financing transaction	22-12-20	CI
Vivo Bio Tech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Vivo Bio Tech Limited Announces Registered Office Address Changes	22-09-29	CI
Vivo Bio Tech Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-10	CI
Vivo Biotech Acquires Land in Telangana, India for $5 Million	22-02-28	MT
Vivo Bio Tech Acquires Land and Building in Telangana, India for Nearly $5 Million	22-02-28	MT
Vivo Bio Tech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-02	CI
Vivo Bio Tech to Set Up New Facility in Andhra Pradesh, India	22-01-30	MT
Vivo Bio Tech Limited Executes a Lease Deed with M/S. Andhra Pradesh Med Tech Zone Limited for Setting Up a New Facility at Andhra Pradesh Med Tech Zone-Visakhapatnam	22-01-29	CI
Vivo Bio Tech Limited Announces Change of Registered Office Address	22-01-07	CI
Vivo Bio Tech Limited Announces Board Appointments	22-01-07	CI
Vivo Bio Tech's CFO Tenders Resignation	21-11-02	MT
Vivo Bio Tech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-02	CI

Chart Vivo Bio Tech Limited

Duration

Period

More charts

Company Profile

Vivo Bio Tech Limited is a comprehensive pre-clinical clinical research organization (CRO) providing drug development and discovery services company. It operates in biotechnology segment. The Company offering drug development and discovery services to pharmaceutical and biotech companies. The Company offers services in the areas of in vivo and in vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxic kinetic studies, genotoxicity screening, and analytical services. It provides both regulatory and non-regulatory IND enabling preclinical development services. The Company provides screening and evaluating molecules for various pharmacological and therapeutic properties. Specifically for oncology, it provides design and development of syngeneic / xenograft models for evaluation of anti-cancer agent. The Company also customizes In vivo drug metabolism and pharmacokinetics (DMPK) studies to help profile drug candidate in both rodent and non-rodent animal models.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIVO BIO TECH LIMITED	+13.69%	6.87M
MODERNA, INC.	+18.09%	44.48B
LONZA GROUP AG	+44.19%	40.57B
IQVIA HOLDINGS INC.	-8.38%	38.82B
ALNYLAM PHARMACEUTICALS, INC.	+34.66%	32.22B
CELLTRION, INC.	-8.34%	27.84B
ICON PUBLIC LIMITED COMPANY	+16.10%	26.79B
UNITED THERAPEUTICS CORPORATION	+49.73%	14.31B
MEDPACE HOLDINGS, INC.	+36.71%	12.7B
BIO-TECHNE CORPORATION	-6.60%	11.23B

Other Biotechnology & Medical Research